The paper presents a new case of neuronal intermediate filament inclusion disease (NIFID), a recently described new variant of early-onset frontotemporal dementia. Documented with repetitive brain images, morphologically proven cases additionally endorse evolving the clinical and pathological phenotype of NIFID. For the first time the paper describes the probable influence of NIFID on the artistic creativity of an accomplished artist showing rapid dissolution of artistic talent.

Keywords:
Neuronal intermediate filament inclusion disease, Frontotemporal dementia, Artistic creativity
1.
Chang Mell J, Howard SM, Miler BL: Art and the brain: the influence of frontotemporal dementia on an accomplished artist. Neurology 2003;60:1707–1710.
2.
Cummings JL, Zarit JM: Probable Alzheimer’s disease in an artist. JAMA 1987;258:2731–2734.
3.
Fornazzari LR: Preserved painting creativity in an artist with Alzheimer’s disease. Eur J Neurol 2005;12:419–424.
4.
Kleiner-Fisman G, Black SE, Lang AE: Neurodegenerative disease and the evolution of art: the effects of presumed corticobasal degeneration in a professional artist. Mov Disord 2002;18:294–302.
5.
Maurer K, Prvulovic D: Paintings of an artist with Alzheimer’s disease: visuoconstructural deficits during dementia. J Neural Transm 2004;111:235–245.
6.
Miller BL, Ponton M, Benson DF, Cummings JL, Mena I: Enhanced artistic creativity with temporal lobe degeneration. Lancet 1996;348:1744–1748.
7.
Miller BL, Cummings J, Mishkin F, Boone K, Prince F, Ponton M, Cotman C: Emergence of artistic talent in frontotemporal dementia. Neurology 1998;51:978–982.
8.
Miller BL, Hou CE: Portraits of artists: emergence of visual creativity in dementia. Arch Neurol 2004;61:842–844.
9.
Maurer K, Volk S, Gerbaldo H: Auguste D and Alzheimer’s disease. Lancet 1997;349:1546–1549.
10.
Cairns NJ, Grossman M, Arnold SE, Burn DJ, Jaros E, Perry RH, Duyckaerts C, Stankoff B, Pillon B, Skullerud K, Cruz-Sanchez FF, Bigio EH, Mackenzie IRA, Gearing M, Juncos JL, Glass JD, Yokoo H, Nakazato I, Mosaheb S, Thorpe JR, Uryu K, Lee VMY, Trojanovski JQ: Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology 2004;63:1376–1384.
11.
Josephs KA, Holton JL, Rossor MN, Braengaard H, Ozawa T, Fox NC, Petersen RC, Pearl GS, Ganguly M, Rosa P, Laursen H, Parisi JE, Waldemar G, Quinn NP, Dickson DW, Revesz T: Neurofilament inclusion body disease: a new proteinopathy? Brain 2003;126:2291–2303.
12.
DeKosky ST, Ikonomovic MD: NIFID: a new molecular pathology with a frontotemporal dementia phenotype. Neurology 2004;63:1348–1349.
13.
Josephs KA, Uchikado H, McComb RD, Bashir R, Wszolek Z, Swanson J, Matsumoto J, Shaw G, Dickson DW: Extending the clinical spectrum of neurofilament inclusion disease. Acta Neuropathol 2005;109:427–432.
14.
Mackenzie IRA, Feldman H: Neurofilament inclusion body disease with early onset frontotemporal dementia and primary lateral sclerosis. Clin Neuropathol 2004;23:183–193.
15.
Mendez MF: Dementia as a window to the neurology of art. Med Hypotheses 2004;63:1–7.
16.
Gordon N: Unexpected development of artistic talents. Postgrad Med J 2005;81:753–755.
17.
Miller BL, Seeley WW, Mychack P, Rosen HL, Mena I, Boone K: Neuroanatomy of the self: evidence from patients with frontotemporal dementia. Neurology 2001;57:817–821.
18.
Crutch SJ, Isaacs R, Rossor MN: Some workmen can blame their tools: artistic change in an individual with Alzheimer’s disease. Lancet 2001;357:2129–2133.
19.
Maurer K, Frölich L: Paintings of an artist with progressive Alzheimer’s disease. Alzheimers Insights 2005;6:11.
20.
Bogousslavsky J: Artistic creativity, style and brain disorders. Eur Neurol 2005;54:103–111.
21.
Espinel CH: De Kooning’s late colours and forms: dementia, creativity, and the healing power of art. Lancet 1996;347:1096–1098.
22.
Wijk H, Berg S, Sivik L, Steen B: Colour discrimination, colour naming and colour preferences among individuals with Alzheimer’s disease. Int J Geriatr Psychiatry 1999;14:1000–1005.
23.
Sahlas DJ: Dementia with Lewy bodies and the neurobehavioral decline of Mervyn Peake. Arch Neurol 2003;60:889–892.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.